Clinical trials: Adult Growth Hormone Deficiency
Growth Hormone Disorder, Adult Growth Hormone Deficiency
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of…
- Conditions
- Growth Hormone Disorder, Adult Growth Hormone Deficiency, Growth Hormone Deficiency in Children, Healthy
- Trial name
- NCT01514500
- Testing
- somapacitan
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Novo Nordisk A/S
Pediatric Growth Hormone Deficiency (PGHD)
A Bioequivalence Study of Two Different PEG-rhGH Preparations.
The purpose of this study is to investigate whether PEG-rhGH with new preparation is bioequivalent to PEG-rhGH with present preparation.
- Trial name
- NCT06331026
- Testing
- PEG-rhGH with new preparation (T), PEG-rhGH with present preparation (R)
- Where
- China
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Growth Hormone Deficiency
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
This study assesses the safety and tolerability of weekly TV-1106 compared to daily rhGH in adults with GHD who have previously been treated with rhGH.
- Trial name
- NCT02410356
- Testing
- TV-1106, dGH
- Where
- 50 sites in United States, Austria and 6 more
- Volunteers
- 34 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Growth Hormone Deficiency
VRS-317 in Adult Subjects With Growth Hormone Deficiency
The purpose of this research study is to determine the safety and tolerability of up to five doses of VRS-317 in Adult Growth Hormone Deficient patients.
- Trial name
- NCT01359488
- Testing
- VRS-317
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Versartis Inc.
Growth Hormone Deficiency
Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)
As studies demonstrate, the administration of recombinant human GH (rhGH) in adults with GH deficiency has been known to improve metabolic impairment and quality of life.
- Trial name
- NCT01605331
- Testing
- sustained-release recombinant human GH (SR-rhGH)
- Volunteers
- 132 people
- Sponsor
- LG Life Sciences
Growth Hormone Disorder, Adult Growth Hormone Deficiency
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, availability and distribution in the body of once-weekly long-acting growth hormone (NNC0195-0092, somapacitan) compared to once…
- Trial name
- NCT01706783
- Testing
- somapacitan, Norditropin NordiFlex®
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 35 people
- Sponsor
- Novo Nordisk A/S
Pediatric Growth Hormone Deficiency (PGHD)
A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different Preparations
The purpose of this study is to compare the pharmacokinetics of the two different PEG-rhGH preparations after a single administration.
- Trial name
- NCT06135168
- Testing
- PEG-rhGH with new preparation, PEG-rhGH with present preparation
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Adult Growth Hormone Deficiency
Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency
To evaluate long-term safety of growth hormone replacement in adult patients with growth hormone deficiency
- Trial name
- NCT00191360
- Testing
- Somatropin
- Where
- 14 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Adult Growth Hormone Deficiency
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
In this study, the general long-term safety and effectiveness of Sogroya (somapacitan) in adults with growth hormone deficiency (AGHD) being treated per normal clinical practice is looked into.
- Trial name
- NCT05718570
- Testing
- Somapacitan
- Where
- 55 sites in United States, France and 4 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency
A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency
The purpose of this study is to explore the safety, toleration and dose response of PHA-794428 after multiple weekly injections in male and female growth hormone deficient patients.
- Trial name
- NCT00308464
- Testing
- PHA-794428
- Where
- 35 sites in Belgium, Czechia and 10 more
- Volunteers
- 136 people
- Sponsor
- Pfizer
Pituitary Disorders, Adult Growth Hormone Deficiency
Treatment of Adults With Growth Hormone Deficiency
The purpose of this study is to evaluate efficacy and safety profile of a new weekly administered growth hormone preparation compared with placebo in adults with growth hormone deficiency.
- Trial name
- NCT00294619
- Testing
- growth hormone
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- LG Life Sciences
Growth Hormone Disorder, Adult Growth Hormone Deficiency
A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
This trial is conducted in Asia. The aim of this trial is to evaluate the safety of once weekly dosing of somapacitan (NNC0195-0092) and daily Norditropin® FlexPro® for 52 weeks in previously human growth hormone treated Japanese…
- Trial name
- NCT03075644
- Testing
- somapacitan, Norditropin
- Where
- 12 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency
Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency
The aim of the study is to determine the specificity and sensitivity of the combined growth hormone releasing hormone (GHRH) + Arginine test in healthy volunteers, subjects with highly probable adult growth hormone deficiency…
- Trial name
- NCT01060488
- Testing
- GHRH+Arg, GHRH+Arg, ITT, ITT, ITT, GHRH+Arg.
- Where
- France
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Growth Hormone Disorders
A Post Marketing Surveillance Study for NutropinAq® in Adults With Growth Hormone Deficiency
This study is a multicenter, open-label, observational, post marketing surveillance program to collect information on the use of NutropinAq® in adults suffering from Growth Hormone Deficiency in Germany, Italy, and United Kingdom
- Trial name
- NCT00455884
- Where
- United Kingdom
- Volunteers
- 546 people
- Sponsor
- Ipsen
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)
This trial is conducted in Japan. To investigate the long-term efficacy as assessed by change in fat mass and safety after 48 weeks of treatment of Growth Hormone in adults with Growth Hormone Deficiency, comparing two different…
- Trial name
- NCT00184743
- Testing
- somatropin
- Where
- Japan
- Volunteers
- 112 people
- Sponsor
- Novo Nordisk A/S
Adult Growth Hormone Deficiency, Endocrine System Diseases
A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
This was a phase 3 open-label multicenter extension study designed to evaluate the long-term safety and efficacy of Lonapegsomatropin administered once-weekly.
- Conditions
- Adult Growth Hormone Deficiency, Endocrine System Diseases, Hormone Deficiency
- Trial name
- NCT05171855
- Testing
- Lonapegsomatropin
- Where
- 85 sites in United States, Armenia and 19 more
- Volunteers
- 220 people
- Sponsor
- Ascendis Pharma Endocrinology Division A/S
Growth Hormone Disorder, Adult Growth Hormone Deficiency
Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function
The trial is conducted in Europe. The aim of the trial is to investigate the steady state exposure of somapacitan in subjects with various degrees of renal impairment (mild, moderate, severe renal impairment, requiring…
- Conditions
- Growth Hormone Disorder, Adult Growth Hormone Deficiency, Growth Hormone Deficiency in Children
- Trial name
- NCT03186495
- Testing
- Somapacitan
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Novo Nordisk A/S
Adult Growth Hormone Deficiency, Growth Hormone Disorder
A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency
This trial is conducted in Europe and Asia. The aim of the trial is to compare the safety of once weekly dosing of somapacitan (administered with an investigational pen) with daily Norditropin® FlexPro® (somatropin delivered…
- Trial name
- REAL 2 (NCT02382939)
- Testing
- somapacitan, somatropin
- Where
- 28 sites in Denmark, France and 4 more
- Volunteers
- 92 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Disorder, Adult Growth Hormone Deficiency
French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin
This study is conducted in Europe. The aim of this study is to extract data from the French National Registry holding information about patients having initiated growth hormone therapy with the objective to describe patients…
- Trial name
- NCT01580605
- Testing
- somatropin
- Where
- France
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Disorder, Adult Growth Hormone Deficiency
An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®
This observational study is conducted in Europe. The aim of this observational study is to investigate the changes in a score (GET-score) which includes quality of life, body composition and cholesterol metabolism in patients on…
- Trial name
- GET (NCT00934063)
- Testing
- somatropin, No treatment given
- Where
- Germany
- Volunteers
- 121 people
- Sponsor
- Novo Nordisk A/S